Waltham, MA — Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company’s Inherent Health® Weight Management Genetic Test. The granted patent, entitled “Genetic Markers for Weight Management and Methods of Use Thereof,” has claims covering methods of determining a subject’s metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject’s metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.
“This newly granted patent expands our intellectual property portfolio and further supports our goal of maximizing the commercial potential of our Weight Management Genetic Test in markets worldwide, including Europe, where the test is currently offered and sold,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. He continued, “This innovative test panel involves Single Nucleotide Polymorphisms combined into novel genetic patterns that can be used by healthcare professionals and individuals to help identify effective ways to achieve more meaningful weight loss.”
The new European patent extends the scope and longevity of Interleukin’s intellectual property portfolio and reinforces its Inherent Health® brand of genetic tests. The Company currently owns ten issued U.S. patents that have expiration dates between 2015 and 2029 and six additional pending U.S. patent applications that are based on novel associations of gene variations and specific metabolic and inflammatory conditions or disorders. In addition, the Company owns a number of foreign patents and pending patent applications corresponding to its U.S. patents and pending U.S. patent applications.
About Interleukin’s Weight Management Genetic Test
Interleukin Genetics’ Weight Management Genetic Test, sold under the Inherent Health® brand, helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test determines whether a low fat, low carbohydrate or balanced diet may be best, and whether normal or vigorous exercise is needed to most efficiently lose existing body fat. The test provides new information beyond traditional assessments so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five Single Nucleotide Polymorphisms (SNPs) in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 – two SNPs); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR-γ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens. Additional information on Interleukin’s Weight Management Genetic Test is available at http://www.inherenthealth.com/our-tests/weight-management.aspx.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility and its Inherent Health® Weight Management Genetic Test that identifies the most effective diet and exercise programs for an individual, based on an individual’s genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.